Three-years experience with Neoral C₂ monitoring adjusted to a target range of 500–600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy

Abstract

Adoption of C(2)-CsA monitoring resulted in a substantial reduction in Neoral dose, while the overall renal graft function remained stable.

TGF-β1 Expression in Kidney Allograft Protocol Biopsies during Cyclosporine: a Therapy

“…Cyclosporine trough levels (C0) have been traditionally used in the follow-up of kidney transplant recipients, although the correlation of these trough levels with the exposure to CsA is poor (21). Several studies suggest that the switch from C0 to C2 monitoring results in reduced CsA-doses, less acute rejections and even better kidney graft function (22, 23). This may be due to the fact that patients monitored with C0 could have been overexposed to CsA (24).…”

“…This may be due to the fact that patients monitored with C0 could have been overexposed to CsA (24). In maintenance phase over one year from transplantation, an adequate C2 target has been suggested by some authors to be lowered to a range between 700 μg/l and 800 μg/l (25) or even lower, from 500 μg/l to 600 μg/l (23).…”